Journal Club Discusses JAK Inhibitors

Join us for another Psound Bytes Journal Club episode discussing noteworthy publications in psoriatic disease. In this episode, we discuss recent research and advancements with JAK inhibitors with Dr. Andrew Blauvelt, President, Oregon Medical Research Center in Portland, OR.

Publications:

Chimalakonda A, Burke J, Cheng L, et al. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763-1776. doi:10.1007/s13555-021-00596-8

Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148-157. doi:10.1016/j.jaad.2021.06.869

Abduelmula A, Gooderham MJ. TYK2 inhibition: changing the treatment landscape for psoriasis? [published online ahead of print, 2021 Nov 23]. Expert Rev Clin Immunol. 2021;1-3. doi:10.1080/1744666X.2022.2008240

McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study [published correction appears in RMD Open. 2021 Nov;7(3):]. RMD Open. 2021;7(3):e001838. doi:10.1136/rmdopen-2021-001838

Wohlrab J, Stintzing D, Schultz L, Jügelt K, Schroeder OH. Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch [published online ahead of print, 2021 Sep 16]. Skin Pharmacol Physiol. 2021;10.1159/000519669. doi:10.1159/000519669

Słuczanowska-Głąbowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A. Role of Janus Kinase Inhibitors in Therapy of Psoriasis. J Clin Med. 2021;10(19):4307. Published 2021 Sep 22. doi:10.3390/jcm10194307

Barnard, C. FDA approves upadacitinib for selected psoriatic arthritis patients. medwireNews. 2021 Dec 20. Accessed 2022 Jan 19. https://www.medwirenews.com/rheumatology/fda-approval/19968574

This program is supported by educational grants from AbbVie, Amgen, Janssen and UCB.